Results 81 to 90 of about 19,369 (169)

SIRT7 Orchestrates Ligand‐Dependent ERα Signaling Rewiring to Drive Tamoxifen Resistance in ERα‐positive Breast Cancer

MedComm – Oncology, Volume 5, Issue 1, March 2026.
In tamoxifen‐sensitive breast cancer, SIRT7 deacetylates ERα at lysines 302 and 303, promoting CHIP‐mediated, ubiquitin‐dependent proteasomal degradation of ERα and thereby restraining estrogen‐driven tumor growth. By contrast, during tamoxifen treatment, enhanced interaction between SIRT7 and ERα redirects deacetylated ERα toward activation of EGFR ...
Yalan Wu, Huixia Liu, Ye Liu, Yanxue Mei, Mengdi Cao, Guo Li, Ronghui Fan, Junfeng Zhang, Langmei Yang, Jieling Liu, Qi Hou, Jinsong Li, Fujun Dai, Baohua Liu, Xiaolong Tang   +14 more
wiley   +1 more source

Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy

Health Science Reports
Background and Aims Pediatric‐type low‐grade gliomas (pLGGs) are the most common solid tumors in children, with v‐raf murine sarcoma viral oncogene homolog B (BRAF) mutations playing a significant role in their development.
Marrium Sultan Dar, Nayab Shahid, Arisha Waqas, Yumna Arif Baig, Aimen Waqar Khan   +4 more
doaj   +1 more source

The Evolution of Pneumocystis jirovecii Pneumonia Prophylaxis for Pediatric Patients With Extracranial Solid Tumors: A Review of Historical Insights and Future Directions

Pediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
ABSTRACT Pneumocystis jirovecii pneumonia (PJP) remains a modern‐day complication for pediatric patients receiving treatment for extracranial solid tumors (ST), highlighting the need for reconsideration of our current approach toward PJP prophylaxis. This critical review aims to evaluate both universal and risk‐stratified approaches to PJP prophylaxis ...
Kriti Kumar, Denise M. Connolly, Ellen Kellington, Elyse Zelunka, Karla Kerrigan, Furqan Shaikh, Paul C. Nathan, Meredith S. Irwin, Sarah Cohen‐Gogo   +8 more
wiley   +1 more source

Targeting MCL‐1 and MAPK overcomes venetoclax resistance in FLT3‐ITD‐positive AML cells harbouring activating PTPN11 (SHP‐2) mutations

British Journal of Haematology, Volume 208, Issue 3, Page 905-915, March 2026.
Summary Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients ...
Maximilian Fleischmann, Ole Hansen, Diana Voigtländer, Julia Bechwar, Lenny‐Joseph Schwietzer, Sanja Bahr, Ulf Schnetzke, Mike Fischer, Florian H. Heidel, Tina M. Schnöder, Jörg P. Müller, Andreas Hochhaus, Sebastian Scholl   +12 more
wiley   +1 more source

Surgical Outcomes Following Neoadjuvant‐Targeted Therapy for Advanced Differentiated Thyroid Cancer—Real‐World Data

Clinical Endocrinology, Volume 104, Issue 3, Page 270-280, March 2026.
ABSTRACT Background Differentiated thyroid carcinoma (DTC) is typically managed surgically with favourable outcomes. However, surgery may have dire consequences when the tumour invades critical structures. Neoadjuvant therapy with tyrosine kinase inhibitors (TKIs) has emerged as a potential strategy to improve resectability and reduce morbidity in ...
Alexandra Dorman, Genady Shendler, Anton Warshavsky, Nidal Muhanna, Gilad Horowitz, Liyona Kampel Furman, Shahaf Shilo, Ben‐Zion Joshua, Eran Alon, Eric Remer, Galit Avior, Avi Khafif, Orit Gutfeld, Elena Izkhakov, Jobran Mansour, Inbar Finkel   +15 more
wiley   +1 more source

Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

Scientific Reports
Management of melanoma has changed significantly with the discovery of targeted therapies and immune checkpoint inhibitors (ICI). Our aim in the study is to determine which treatment alternatives, specifically dabrafenib plus trametinib and ICIs, are ...
Nargiz Majidova, Hacı Arak, Faruk Recep Ozalp, Onur Bas, Gulhan Ozcelik Koker, Erkan Buket Ozmarasalı, Yasemin Sagdıc Karateke, Teoman Sakalar, Sendag Yaslikaya, Ilknur Deliktas Onur, Goncagul Akdag, Ali Ogul, Murad Guliyev, Elif Sahin, Ebru Engin Delipoyraz, Ali Alkan, Okan Aydın, Nurullah Ilhan, Ozkan Alan, Sinem Akbas, Yaprak Cağlar, Ali Kaan Guren, Nadiye Sever, Halil Ibrahim Ellez, Fatih Selcukbiricik, Mustafa Muhammed Atcı, Ahmet Bilici, Nebi Serkan Demirci, Tugba Basoglu, Cengiz Karacin, Ismail Oguz Kara, Bulent Yıldız, Turkkan Evrensel, Mustafa Karaca, Omer Dizdar, Elif Atag, Alpaslan Ozgun, Osman Kostek   +37 more
doaj   +1 more source

Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome

Frontiers in Pediatrics
IntroductionRare pathogenic variants in the PTPN11, KRAS, SOS1 and RAF1 genes are the main molecular causes of Noonan syndrome (NS). Most are dominant gain-of-function variants that cause an overactivation of the RAS/MAPK signaling pathway leading to ...
Isabel De Brouchoven, Juan Lorand, Léon Bofferding, Arthur Sorlin, An Van Damme, Olivier Danhaive, Olivier Danhaive   +6 more
doaj   +1 more source

Deep Dermal and Subcutaneous Deposits in Thin Melanoma: A Cautionary Tale

Journal of Cutaneous Pathology, Volume 53, Issue 3, Page 224-229, March 2026.
ABSTRACT Melanoma microsatellites are peritumoral metastatic deposits and surrogates for potentially aggressive biological behavior. Their presence indicates clinical stage III disease. They are rarely reported in association with thin primary tumors (< 1.0 mm, pT1).
Angela Cheng, Jennette Gruchy, Ariel Burns, Richard Langley, Jason Williams, Ryan DeCoste   +5 more
wiley   +1 more source

Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation

IJU Case Reports
Introduction BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma. Case presentation A 60‐year‐old male was diagnosed with muscle‐invasive bladder cancer and underwent total cystectomy ...
Hiroyuki Karasawa, Yota Yasumizu, Takeo Kosaka, Tatsunori Shimoi, Mototsugu Oya   +4 more
doaj   +1 more source

Precision medicine in cutaneous melanoma—A comprehensive review

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 3, Page 377-386, March 2026.
Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley   +1 more source